Loading...
Loading...
ALGS| Name | Value |
|---|---|
| Revenues | 2.7M |
| Cost of Revenue | 0.8M |
| Gross Profit | 1.9M |
| Operating Expense | 27.9M |
| Operating I/L | -26.0M |
| Other Income/Expense | -1.9M |
| Interest Income | 1.6M |
| Pretax | -27.9M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -27.9M |
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutics for viral and liver diseases. The company's lead drug candidates, including ALG-010133 and ALG-000184, are in clinical trials for the treatment of chronic hepatitis B (CHB). Additionally, Aligos is developing other promising drug candidates such as ALG-020572 and ALG-055009 for the treatment of hepatitis B and non-alcoholic steatohepatitis (NASH), respectively. The company has also entered into strategic collaborations to develop and commercialize products targeting hepatitis B virus and coronavirus protease inhibitors, demonstrating a strong focus on advancing its pipeline and generating revenue through partnerships and product commercialization.
